Tokyo, Aug. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062309) titled 'Real-world clinical outcomes of adjuvant pembrolizumab following surgery for high-risk renal cell carcinoma: a multicenter retrospective study (SHINSHU study)' on Aug. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Shinshu university
Condition:
Condition - renal cell carcinoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the natural course of renal cell carcinoma after surgery
Basic objectives2 - Others
Eligibility:
Age-lower limit - 20
years-old
=
Gender - Male and Female
Key inclusion criteria - Renal cell carcinoma patients who received surgery
Key exclusion criteria - None
Target Size - 100
Recruitment Status:
Recruitment status - Completed
Date of protocol fixation - 2025 Year 05 Month 18 Day
Date of IRB - 2025 Year 07 Month 18 Day
Anticipated trial start date - 2025 Year 07 Month 20 Day
Last follow-up date - 2026 Year 01 Month 01 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071305
Disclaimer: Curated by HT Syndication.
